VAPC, an human endogenous inhibitor for hepatitis C virus (HCV) infection, is intrinsically unstructured but forms a "fuzzy complex" with HCV NS5B

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Goyal, Shaveta ^a   Gupta, Garvita ^b   Qin, Haina ^b   Upadya, Megha Haridas ^a   Tan, Yee Joo ^a   Chow, Vincent T K ^a   Song, Jianxing ^a,b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN; UNCLASSIFIED DRUG; VAPB PROTEIN; VAPC PROTEIN; VISICLE ASSOCIATED MEMBRANE PROTEIN ASSOCIATED PROTEIN C;

AMINO TERMINAL SEQUENCE; ARTICLE; BINDING AFFINITY; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CIRCULAR DICHROISM; COMPLEX FORMATION; DISSOCIATION CONSTANT; HEPATITIS C VIRUS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN STRUCTURE; VIRUS STRAIN;

AMINO ACID SEQUENCE; HEPACIVIRUS; HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY; VESICULAR TRANSPORT PROTEINS; VIRAL NONSTRUCTURAL PROTEINS;

HEPATITIS C VIRUS;

EID: 84864012621     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040341     Document Type: Article

References (74)

1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, et al. ((1989)) Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244: 359-562.
2. Fusco DN, Chung RT, ((2012)) Novel therapies for hepatitis C: insights from the structure of the virus. Annu. Rev. Med. 63: 373-387.
3. Wasley A, Alter MJ, ((2000)) Epidemiology of hepatitis C: geographic differences and temporal trends. Semin. Liver Dis. 20: 1-16.
4. Zoulim F, Chevallier M, Maynard M, Trepo C, ((2003)) Clinical consequences of hepatitis C virus infection. Rev. Med. Virol. 13: 57-68.
5. Dubuisson J, Helle F, Cocquerel L, ((2008)) Early steps of the hepatitis C virus life cycle. Cell. Microbiol. 10: 821-827.
6. Hijikata M, Mizushima H, Tanji Y, Komoda Y, Hirowatari Y, et al. ((1993)) Proteolytic processing and membrane association of putative nonstructural proteins of hepatitis C virus. Proc. Natl. Acad. Sci. USA 90: 10773-10777.
7. Moriishi K, Matsuura Y, ((2003)) Mechanisms of hepatitis C virus infection. Antivir. Chem. Chemother. 14: 285-297.
8. Grakoui A, Wychowski C, Lin C, Feinstone SM, Rice CM, ((1993)) Expression and identification of hepatitis C virus polyprotein cleavage products. J. Virol. 67: 1385-1395.
9. Lohmann V, Koch JO, Bartenschlager R, ((1996)) Processing pathways of the hepatitis C virus proteins. J. Hepatol. 24: 11-19.
10. Shi ST, Lee KJ, Aizaki H, Hwang SB, Lai MM, ((2003)) Hepatitis C virus RNA replication occurs on a detergent-resistant membrane that cofractionates with caveolin-2. J. Virol. 77: 4160-4168.
11. Aizaki H, Lee K, Sung VMH, Ishiki H, Lai MMC, ((2004)) Characterization of the hepatitis C virus RNA replication complex associated with lipid rafts. Virology 324: 450-461.
12. Ali N, Tardif KD, Siddiqui A, ((2002)) Cell-free replication of the hepatitis C virus subgenomic replicon. J. Virol. 76: 12001-12007.
13. Hardy RW, Marcotrigiano J, Blight KJ, Majors JE, Rice CM, ((2003)) Hepatitis C virus RNA synthesis in a cell-free system isolated from replicon-containing hepatoma cells. J. Virol. 77: 2029-2037.
14. Yang G, Pevear DC, Collett MS, Chunduru S, Young DC, et al. ((2004)) Newly synthesized hepatitis C virus replicon RNA is protected from nuclease activity by a protease-sensitive factor(s). J. Virol. 78: 10202-10205.
15. Gao L, Aizaki H, He JW, Lai MMC, ((2004)) Interactions between viral nonstructural proteins and host protein hVAP-33 mediate the formation of hepatitis C virus RNA replication complex on lipid raft. J. Virol. 78: 3480-3488.
16. Evans MJ, Rice CM, Goff SP, ((2004)) Phosphorylation of hepatitis C virus nonstructural protein 5A modulates its protein interactions and viral RNA replication. Proc. Natl. Acad. Sci. USA 101: 13038-12043.
17. Hamamoto I, Nishimura Y, Okamoto T, Aizaki H, Liu M, et al. ((2005)) Human VAP-B is involved in hepatitis C virus replication through interaction with NS5A and NS5B. J. Virol. 79: 13473-13482.
18. Ghany MG, Strader DB, Thomas DL, Seeff LB, ((2009)) Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49: 1335-1374.
19. Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, et al. ((2011)) A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472: 481-485.
20. Rice CM, ((2011)) New insights into HCV replication: potential antiviral targets. Top. Antivir. Med. 19: 117-20.
21. Bühler S, Bartenschlager R, ((2012)) New targets for antiviral therapy of chronic hepatitis C. Liver Int. 32 Suppl 1: 9-16.
22. Sarrazin C, Hézode C, Zeuzem S, Pawlotsky JM, ((2012)) Antiviral strategies in hepatitis C virus infection. J. Hepatol. 56 Suppl: S88-S100.
23. Ashfaq UA, Javed T, Rehman S, Nawaz Z, Riazuddin S, ((2011)) An overview of HCV molecular biology, replication and immune responses. Virol. J. 8: 161.
24. Behrens SE, Tomei L, de Francesco R, ((1996)) Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus. EMBO J. 15: 12-22.
25. Kwo PY, Vinayek R, ((2011)) The therapeutic approaches for hepatitis C virus: protease inhibitors and polymerase inhibitors. Gut Liver. 5: 406-417.
26. Halfon P, Locarnini S, ((2011)) Hepatitis C virus resistance to protease inhibitors. J. Hepatol. 55: 192-206.
27. Watashi K, Hijikata M, Hosaka M, Yamaji M, Shimotohno K, ((2003)) Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 38: 1282-1288.
28. Kaul A, Stauffer S, Berger C, Pertel T, Schmitt J, et al. ((2009)) Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics. PLoS Pathog. 5: e1000546.
29. Tellinghuisen TL, Foss KL, Treadaway JC, Rice CM, ((2008)) Identification of residues required for RNA replication in domains II and III of the hepatitis C virus NS5A protein. J. Virol. 82: 1073-1083.
30. Yamasaki LH, Arcuri HA, Jardim AC, Bittar C, de Carvalho-Mello IM, et al. ((2012)) New insights regarding HCV-NS5A structure/function and indication of genotypic differences. Virol. J. 9: 14.
31. Kukihara H, Moriishi K, Taguwa S, Tani H, Abe T, et al. ((2009)) Human VAP-C negatively regulates hepatitis C virus propagation. J. Virol. 83: 7959-7969.
32. Wen X, Abe T, Kukihara H, Taguwa S, Mori Y, et al. ((2011)) Elimination of hepatitis C virus from hepatocytes by a selective activation of therapeutic molecules. PLoS One 6: e15967.
33. Skehel PA, Martin KC, Kandel ER, Bartsch D, ((1995)) AVAMP-binding protein from Aplysia required for neurotransmitter release. Science 269: 1580-1583.
34. Nishimura Y, Hayashi M, Inada H, Tanaka T, ((1999)) Molecular cloning and characterization of mammalian homologues of vesicle-associated membrane protein-associated (VAMP-associated) proteins. Biochem. Biophys. Res. Commun. 254: 21-26.
35. Nachreiner T, Esser M, Tenten V, Troost D, Weis J, et al. ((2010)) Novel splice variants of the amyotrophic lateral sclerosis-associated gene VAPB expressed in human tissues. Biochem. Biophys. Res. Commun. 394: 703-708.
36. Kaiser SE, Brickner JH, Reilein AR, Fenn TD, Walter P, et al. ((2005)) Structural basis of FFAT motif-mediated ER targeting. Structure 13: 1035-1045.
37. Shi J, Lua S, Tong JS, Song J, ((2010)) Elimination of the native structure and solubility of the hVAPB MSP domain by the Pro56Ser mutation that causes amyotrophic lateral sclerosis. Biochemistry 49: 3887-3897.
38. Lua S, Qin H, Lim L, Shi J, Gupta G, et al. ((2011)) Structural, stability, dynamic and binding properties of the ALS-causing T46I mutant of the hVAPB MSP domain as revealed by NMR and MD simulations. PLoS One 6: e27072.
39. Skehel PA, Fabian-Fine R, Kandel ER, ((2000)) Mouse VAP33 is associated with the endoplasmic reticulum and microtubules. Proc. Natl. Acad. Sci. USA 97: 1101-1106.
40. Olkkonen VM, ((2004)) Oxysterol binding protein and its homologues: New regulatory factors involved in lipid metabolism. Curr. Opin. Lipidol. 15: 321-327.
41. Wyles JP, McMaster CR, Ridgway ND, ((2002)) Vesicle associated membrane protein-associated protein-A (VAP-A) interact with the oxysterol-binding protein to modify export from the endoplasmic reticulum. J. Biol. Chem. 277: 29908-29918.
42. Tsuda H, Han SM, Yang Y, Tong C, Lin YQ, et al. ((2008)) The amyotrophic lateral sclerosis 8 protein VAPB is cleaved, secreted, and acts as a ligand for Eph receptors. Cell 133: 963-977.
43. Nishimura AL, Al-Chalabi A, Zatz M, ((2005)) A common founder for amyotrophic lateral sclerosis type 8 (ALS8) in the Brazilian population. Hum. Genet. 118: 499-500.
44. Chen HJ, Anagnostou G, Chai A, Withers J, Morris A, et al. ((2010)) Characterization of the properties of a novel mutation in VAPB in familial amyotrophic lateral sclerosis. J. Biol. Chem. 285: 40266-40281.
45. Penin F, Dubuisson J, Rey FA, Moradpour D, Pawlotsky JM, ((2004)) Structural biology of hepatitis C virus. Hepatology 39: 5-19.
46. Dyson HJ, Wright PE, ((2001)) Nuclear magnetic resonance methods for elucidation of structure and dynamics in disordered states. Methods Enzymol. 339: 258-270.
47. Bai Y, Chung J, Dyson HJ, Wright PE, ((2001)) Structural and dynamic characterization of an unfolded state of poplar apoplastocyanin formed under nondenaturing conditions. Protein Sci. 10: 1056-1066.
48. Liu J, Li M, Ran X, Fan JS, Song J, ((2006)) Structural insight into the binding diversity between the human Nck2 SH3 domains and proline-rich proteins. Biochemistry 45: 7171-7184.
49. Miao L, Qin H, Koehl P, Song J, ((2011)) Selective and specific ion binding on proteins at physiologically-relevant concentrations. FEBS Lett. 585: 3126-3132.
50. Garnier J, Gibrat JF, Robson B, ((1996)) GOR secondary structure prediction method version IV. Methods Enzymol. 266: 540-553.
51. Frishman D, Argos P, ((1996)) Incorporation of non-local interactions in protein secondary structure prediction from the amino acid sequence. Protein Eng. 9: 133-142.
52. Levin J, ((1997)) Exploring the limits of nearest neighbor secondary structure prediction. Protein Eng. 7: 771-776.
53. Minor DL Jr, Kim PS, ((1994)) Context is a major determinant of β-sheet propensity. Nature 371: 264-267.
54. Minor DL Jr, Kim PS, ((1996)) Context-dependent secondary structure formation of a designed protein sequence. Nature 380: 730-734.
55. Liu J, Song J, ((2008)) NMR evidence for forming highly populated helical conformations in the partially folded hNck2 SH3 domain. Biophys. J. 95: 4803-4812.
56. Rösner HI, Poulsen FM, ((2010)) Residue-specific description of non-native transient structures in the ensemble of acid-denatured structures of the all-beta protein c-src SH3. Biochemistry 49: 3246-3253.
57. Liu J, Song J, ((2009)) Insights into protein aggregation by NMR characterization of insoluble SH3 mutants solubilized in salt-free water. PLoS One 4: e7805.
58. Dyson HJ, Wright PE, ((2005)) Intrinsically unstructured proteins and their functions. Nat. Rev. Mol. Cell Biol. 6: 197-208.
59. Tompa P, ((2002)) Intrinsically unstructured proteins. Trends Biochem. Sci. 27: 527-533.
60. Gunasekaran K, Tsai CJ, Kumar S, Zanuy D, Nussinov R, ((2003)) Extended disordered proteins: targeting function with less scaffold. Trends Biochem. Sci. 28: 81-85.
61. Wright PE, Dyson HJ, ((1999)) Intrinsically unstructured proteins: re-assessing the protein structure-function paradigm. J. Mol. Biol. 293: 321-331.
62. Dunker AK, Lawson JD, Brown CJ, Williams RM, Romero P, et al. ((2001)) Intrinsically disordered protein. J. Mol. Graph Model. 19: 26-59.
63. Song J, Chen Z, Xu P, Gingras R, Ng A, et al. ((2001)) Molecular interactions of the Gb binding domain of the Ste20p/PAK family of protein kinases. An isolated but fully functional Gb binding domain from Ste20p is only partially folded as shown by heteronuclear NMR spectroscopy. J. Biol. Chem. 276: 41205-41212.
64. Li M, Song J, ((2007)) The N- and C-termini of the human Nogo molecules are intrinsically unstructured: bioinformatics, CD, NMR characterization, and functional implications. Proteins 68: 100-108.
65. Liu J, Song J, ((2008)) A novel nucleolar transcriptional activator ApLLP for long-term memory formation is intrinsically unstructured but functionally active. Biochem. Biophys. Res. Commun. 366: 585-91.
66. Tompa P, Fuxreiter M, ((2008)) Fuzzy complexes: polymorphism and structural disorder in protein-protein interactions. Trends Biochem Sci. 33: 2-8.
67. Fuxreiter M, ((2012)) Fuzziness: linking regulation to protein dynamics. Mol. Biosyst. 8: 168-177.
68. Song J, Ni F, ((1998)) NMR for the design of functional mimetics of protein-protein interactions: one key is in the building of bridges. Biochem. Cell Biol. 76: 177-188.
69. Cheng Y, LeGall T, Oldfield CJ, Mueller JP, van YY, et al. ((2006)) Rational drug design via intrinsically disordered protein. Trends Biotechnol. 24: 435-442.
70. Metallo SJ, ((2010)) Intrinsically disordered proteins are potential drug targets. Curr Opin Chem Biol. 14: 481-488.
71. Goh PY, Tan YJ, Lim SP, Tan YH, Lim SG, et al. ((2004)) Cellular RNA helicase p68 relocalization and interaction with the hepatitis C virus (HCV) NS5B protein and the potential role of p68 in HCV RNA replication. J. Virol. 78: 5288-5298.
72. Pace CN, Vajdos F, Fee L, Grimsley G, Gray T, ((1995)) How to measure and predict the molar absorption coefficient of a protein. Protein Sci. 4: 2411-2423.
73. Delaglio F, Grzesiek S, Vuister GW, Zhu G, Pfeifer J, et al. ((1995)) NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J. Biomol. NMR 6: 277-293.
74. Johnson BA, Blevins RA, ((1994)) NMRView: a computer program for the visualization and analysis of NMR data. J. Biomol. NMR 4: 603-614.